What is BioCryst Pharmaceuticals's net change in cash?

BioCryst Pharmaceuticals (BCRX) reported net change in cash of $82.04M in Q1 2026.

How has BioCryst Pharmaceuticals's net change in cash changed year-over-year?

BioCryst Pharmaceuticals's net change in cash increased by 14602.7% year-over-year, from $558K to $82.04M.

What is the long-term trend for BioCryst Pharmaceuticals's net change in cash?

Over 2 years (2021 to 2025), BioCryst Pharmaceuticals's net change in cash has grown at a -74.7% compound annual growth rate (CAGR), from $233.39M to -$14.99M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

BioCryst Pharmaceuticals BCRX Net Change in Cash

Net Change in Cash at other companies

Ionis PharmaceuticalsIONS

-$198.88M-999%

Ultragenyx PharmaceuticalRARE

-$247M-449%

BridgeBio PharmaBBIO

$309.88M+321%

Arrowhead ResearchARWR

-$14.12M-111%

Agios PharmaceuticalsAGIO

$24.47M+801%

ALN

Alnylam PharmaceuticalsALNY

$53.61M0.0%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's net change in cash?: BioCryst Pharmaceuticals (BCRX) reported net change in cash of $82.04M in Q1 2026.
How has BioCryst Pharmaceuticals's net change in cash changed year-over-year?: BioCryst Pharmaceuticals's net change in cash increased by 14602.7% year-over-year, from $558K to $82.04M.
What is the long-term trend for BioCryst Pharmaceuticals's net change in cash?: Over 2 years (2021 to 2025), BioCryst Pharmaceuticals's net change in cash has grown at a -74.7% compound annual growth rate (CAGR), from $233.39M to -$14.99M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.